Development of a Screening Approach to Interpret Human Biomonitoring Data on Volatile Organic Compounds: Reverse Dosimetry on Biomonitoring Data for Trichloroethylene

A screening approach is developed for volatile organic compounds (VOCs) to estimate exposures that correspond to levels measured in fluids and/or tissues in human biomonitoring studies. The approach makes use of a generic physiologically-based pharmacokinetic (PBPK) model coupled with exposure pattern characterization, Monte Carlo analysis, and quantitative structure property relationships (QSPRs). QSPRs are used for VOCs with minimal data to develop chemical-specific parameters needed for the PBPK model. The PBPK model is capable of simulating VOC kinetics following multiple routes of exposure, such as oral exposure via water ingestion and inhalation exposure during shower events. Using published human biomonitoring data of trichloroethylene (TCE), the generic model is evaluated to determine how well it estimates TCE concentrations in blood based on the known drinking water concentrations. In addition, Monte Carlo analysis is conducted to characterize the impact of the following factors: (1) uncertainties in the QSPR-estimated chemical-specific parameters; (2) variability in physiological parameters; and (3) variability in exposure patterns. The results indicate that uncertainty in chemical-specific parameters makes only a minor contribution to the overall variability and uncertainty in the predicted TCE concentrations in blood. The model is used in a reverse dosimetry approach to derive estimates of TCE concentrations in drinking water based on given measurements of TCE in blood, for comparison to the U.S. EPA's Maximum Contaminant Level in drinking water. This example demonstrates how a reverse dosimetry approach can be used to facilitate interpretation of human biomonitoring data in a health risk context by deriving external exposures that are consistent with a biomonitoring data set, thereby permitting comparison with health-based exposure guidelines.

[1]  J. Hine,et al.  Structural effects on rates and equilibriums. XIX. Intrinsic hydrophilic character of organic compounds. Correlations in terms of structural contributions , 1975 .

[2]  A. Almatari,et al.  Topical absorption of isopropyl alcohol induced cardiac and neurologic deficits in an adult female with intact skin. , 2000, Veterinary and human toxicology.

[3]  Michael A. Gallo,et al.  Reconstruction of short-term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models , 1994 .

[4]  D Mackay,et al.  Correlation of tissue, blood, and air partition coefficients of volatile organic chemicals. , 1989, British journal of industrial medicine.

[5]  M. Sohn,et al.  Reconstructing population exposures from dose biomarkers: inhalation of trichloroethylene (TCE) as a case study , 2004, Journal of Exposure Analysis and Environmental Epidemiology.

[6]  M. Andersen,et al.  PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF STYRENE AND STYRENE OXIDE RESPIRATORY-TRACT DOSIMETRY IN RODENTS AND HUMANS , 2002, Inhalation toxicology.

[7]  Kannan Krishnan,et al.  Molecular Structure-Based Prediction of the Partition Coefficients of Organic Chemicals for Physiological Pharmacokinetic Models , 1996 .

[8]  F. Lovejoy,et al.  The generation of acetonemia/acetonuria following ingestion of a subtoxic dose of isopropyl alcohol. , 1989, The American journal of emergency medicine.

[9]  L. Wallace,et al.  Personal Exposures, Indoor Outdoor Relationships, and Breath Levels of Toxic Air-Pollutants Measured for 355 Persons in New-Jersey , 1985 .

[10]  Martin P. Payne,et al.  COMPARISON OF MODELS FOR THE ESTIMATION OF BIOLOGICAL PARTITION COEFFICIENTS , 2002, Journal of toxicology and environmental health. Part A.

[11]  K. Krishnan,et al.  Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals. , 2005, Chemical research in toxicology.

[12]  Lance Wallace,et al.  Personal exposures, indoor and outdoor air concentrations, and exhaled breath concentrations of selected volatile organic compounds measured for 600 residents of New Jersey, North Dakota, North Carolina and California† , 1986 .

[13]  Harvey J Clewell,et al.  Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform , 2006, Journal of toxicology and environmental health. Part A.

[14]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[15]  M. Williams-Johnson,et al.  Toxicological profile for trichloroethylene , 1997 .

[16]  M E Andersen,et al.  Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. , 1989, Toxicology and applied pharmacology.

[17]  H J Clewell,et al.  Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. , 1991, Toxicology and applied pharmacology.

[18]  D. Ashley,et al.  Blood concentrations of volatile organic compounds in a nonoccupationally exposed US population and in groups with suspected exposure. , 1994, Clinical chemistry.

[19]  M E Andersen,et al.  Modeling the tissue solubilities and metabolic rate constant (Vmax) of halogenated methanes, ethanes, and ethylenes. , 1988, Toxicology letters.

[20]  P. Levallois,et al.  CANCER RISK ASSOCIATED WITH HOUSEHOLD EXPOSURE TO CHLOROFORM , 2002, Journal of toxicology and environmental health. Part A.

[21]  H J Clewell,et al.  Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  K. Maurer,et al.  Third national health and nutrition examination survey , 1985 .

[23]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.

[24]  Harvey J Clewell,et al.  An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[25]  H J Clewell,et al.  Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. , 2000, Environmental health perspectives.

[26]  Harvey J. Clewell,et al.  Evaluation of the Uncertainty in an Oral Reference Dose for Methylmercury Due to Interindividual Variability in Pharmacokinetics , 1999, Risk analysis : an official publication of the Society for Risk Analysis.

[27]  K. Krishnan,et al.  Molecular Structure-Based Prediction of the Toxicokinetics of Inhaled Vapors in Humans , 1999 .

[28]  Mitchell J. Small,et al.  Inhalation exposure model for volatile chemicals from indoor uses of water , 1992 .

[29]  C. Meulenberg,et al.  Empirical relations predicting human and rat tissue:air partition coefficients of volatile organic compounds. , 2000, Toxicology and applied pharmacology.

[30]  John C. Little,et al.  Applying the two-resistance theory to contaminant volatilization in showers , 1992 .

[31]  J. Hine,et al.  THE INTRINSIC HYDROPHILIC CHARACTER OF ORGANIC COMPOUNDS, CORRELATIONS IN TERMS OF STRUCTURAL CONTRIBUTIONS , 1975 .

[32]  Harvey J Clewell,et al.  Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[33]  P. Mayer.  Residential End Uses of Water , 1999 .

[34]  H J Clewell,et al.  Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.

[35]  Neil E. Klepeis,et al.  Descriptive statistics tables from a detailed analysis of the National Human Activity Pattern Survey (NHAPS) data , 1996 .

[36]  Harvey J Clewell,et al.  Evaluation of Physiologically Based Pharmacokinetic Models in Risk Assessment: An Example with Perchloroethylene , 2005, Critical reviews in toxicology.